13.02.2018 - Danish drugmaker Novo Nordisk has been granted marketing approval by the European Commission for its Ozempic (semaglutide) diabetes treatment. The once-weekly drug, a glucagon-like...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)